Physician profile
Henry S Moon
NPI 1780646083
$1,874.19
in general payments reported to CMS, 2019-2025
26 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.64 · 2020: $201 · 2021: $907 · 2022: $327 · 2023: $123 · 2024: $172 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $422.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $418.67 | 2021-2025 | Rybelsus, Ozempic |
| Paratek Pharmaceuticals, INC. | $269.74 | 2020-2021 | |
| Amarin Pharma, INC. | $170.98 | 2021-2022 | |
| Glaxosmithkline, LLC. | $122.84 | 2020-2023 | Trelegy Ellipta |
| Ibsa Pharma INC. | $111.99 | 2020-2022 | |
| Exact Sciences Corporation | $111.36 | 2023-2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $107.57 | 2020-2024 | Farxiga, Airsupra |
| Abbvie INC. | $97.52 | 2021-2025 | |
| Lilly USA, LLC | $86.24 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Kowa Pharmaceuticals America, INC. | $50.87 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $49.35 | 2024 | Spravato |
| Novartis Pharmaceuticals Corporation | $32.85 | 2022 | |
| Dexcom, INC. | $23.24 | 2024 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $22.22 | 2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $20.26 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $19.35 | 2020 | |
| Nestle Healthcare Nutrition INC. | $17.47 | 2021 | |
| Horizon Therapeutics Plc | $17.10 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.85 | 2021 | |
| Adlon Therapeutics L.P. | $16.80 | 2021 | |
| Medicure Pharma INC. | $16.54 | 2021 | |
| Genentech USA, INC. | $16.38 | 2021 | |
| Amgen INC. | $15.64 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.61 | 2025 | |
| Eisai INC. | $13.97 | 2020 | |
| Currax Pharmaceuticals LLC | $13.78 | 2024 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Moon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.